<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452477</url>
  </required_header>
  <id_info>
    <org_study_id>Tanshinone-HLJUCM</org_study_id>
    <nct_id>NCT01452477</nct_id>
  </id_info>
  <brief_title>Tanshinone in Polycystic Ovary Syndrome</brief_title>
  <official_title>Effect of Tanshinone on Hormonal and Metabolic Features in Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heilongjiang University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heilongjiang University of Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tanshinone was originally isolated from dried roots of Salvia miltiorrhiza bunge. In Chinese
      medicine, this herb has been widely prescribed for several pathologies, including diabetes,
      acne, cardiovascular disease.It has been demonstrated that the therapeutic benefit of
      cryptotanshinone on prenatally androgenized rats may be mediated by its dual regulation of
      key molecules during both insulin signaling and androgen synthesis.The purpose of this study
      is to determine whether tanshinone may prove effective in eradicating Polycystic Ovary
      Syndrome (PCOS) symptomatology.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>basal testosterone</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome measure is a decrease in basal testosterone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian androgen biosynthesis</measure>
    <time_frame>3 months</time_frame>
    <description>Human chorionic gonadotropin (HCG) induced response of androgens including 17-hydroxyprogesterone (17-OHP), androstenedione (A2), testosterone (T)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body insulin action</measure>
    <time_frame>3 months</time_frame>
    <description>Insulin resistance by the glucose disposal rate (GDR) with hyperinsulinemic euglycemic clamp test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral glucose tolerance test (OGTT)</measure>
    <time_frame>3 months</time_frame>
    <description>All the participants will undergo an overnight fast. After ingestion of a 75-g glucose load, blood samples will be obtained at 0, 30, 60, 90, and 120min for glucose and insulin level determination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproductive hormones</measure>
    <time_frame>3 months</time_frame>
    <description>estradiol (E2), 17-α-hydroxyprogesterone (17-OHP), follicle stimulation hormone (FSH), leutinizing hormone (LH), sex hormone binding globulin and dehydroepiandrosterone sulphate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting gluco-lipid metabolic profiles</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>the quality of life will be assessed by the Polycystic Ovary Syndrome Questionnaire (PCOS-QOL)and the Chinese Quality of Life (ChQOL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight, waist/hip circumference, blood pressure, F-G score and acne before and after treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>tanshinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tanshinone placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanshinone</intervention_name>
    <description>tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.</description>
    <arm_group_label>tanshinone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanshinone placebo</intervention_name>
    <description>placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.</description>
    <arm_group_label>tanshinone placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of PCOS diagnosed based on the Androgen Excess Society criteria. All subjects
             must have hyperandrogenism (hirsutism and/or hyperandrogenemia), ovarian dysfunction
             (oligoanovulation and/or polycystic ovaries), and exclusion of other androgen excess
             related disorders. Oligomenorrhea is defined as an intermenstrual interval &gt;35 days or
             &lt;8 menstrual bleedings in the past year. Amenorrhea is defined as an intermenstrual
             interval &gt;90 days. Clinical hyperandrogenism is defined as a Ferriman-Gallwey (FG)
             score ≥5

          -  Age of women from 18 to 35 years；

          -  No desire of children within 6 month and use condoms for contraception.

        Exclusion Criteria:

          -  Use of hormonal drugs or other medications, which can affect the results of the study
             especially Chinese herbal prescriptions in the past 12 weeks；

          -  Patients with other androgen excess endocrine disorders including 21-hydroxylase
             deficiency, hyperprolactinemia, Cushing syndrome, severe insulin resistance, thyroid
             dysfunction；

          -  Patients with history of sever cardiac , pulmonary, hepatic, renal, neurologic disease
             or mental illness；

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoke Wu, docotor</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affliated Hospital,Heilongjiang University of Chinese Medicine .</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoke Wu, MD.PhD.</last_name>
    <phone>13796025599</phone>
    <email>xiaokewu2002@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjuan Shen, doctor</last_name>
      <phone>+86-045182118464</phone>
      <email>shenwenjuankx@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuehui Zhang, doctor</last_name>
      <phone>+86-045182118464</phone>
      <email>manbingPCOS@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wenjuan Shen, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huaian Maternal and Child Health Hospital</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <zip>223001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiying Xue, Scholar</last_name>
      <phone>+8613505238015</phone>
      <email>haxuehuiying@126.com</email>
    </contact>
    <investigator>
      <last_name>Huiying Xue, bachlor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lianyungang Maternal and Child Health Hospital</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>JiangXi University of Traditional Chinese Medicine</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heilongjiang University of Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Xiaoke Wu</investigator_full_name>
    <investigator_title>Professor and Chairman Dept Obs &amp; Gyn, First Affiliated Hospital</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Cryptotanshinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tanshinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

